Suven Life Sciences Ltd has obtained two product patents from New Zealand for its new chemical entities (NCEs) related to the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company, a release issued on Friday said.
They were being developed as therapeutic agents and were useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinsons and schizophrenia.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.